Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia

International Journal of Oncology

Volumn 35, Issue 1, 2009, Pages 87-96

  Paradowska, Agnieszka ^a   Fenic, Irina ^a   Konrad, Lutz ^a   Sturm, Klaus ^a   Wagenlehner, Florian ^a   Weidner, Wolfgang ^a   Steger, Klaus ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

DNA methylation; Genomic imprinting; Post translational modification of histones; Prostate cancer; Prostatic hyperplasia

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BISULFITE; DNA; H19 PROTEIN; HISTONE; HISTONE H3; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN B; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 11P; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC VALUE; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FROZEN SECTION; GENE AMPLIFICATION; GENE EXPRESSION; GENOME IMPRINTING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MODIFICATION; SEQUENCE ANALYSIS;

ACETYLATION; AGED; BINDING SITES; CARCINOMA; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HISTONES; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RACEMASES AND EPIMERASES; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 67649443764     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000316     Document Type: Article

References (40)

1. Reik W and Walter J: Epigenetic reprogramming in mammalian development. Science 293: 1089-1093, 2001.
2. Reik W and Walter J: Genomic imprinting: parental influence on the genome. Nat Rev Genet 1: 21-32, 2001.
3. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE and Feinberg AP: Relaxation of imprinted genes in human cancer. Nature 362: 747-749, 1993.
4. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR and Feinberg AP: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299: 1753-1755, 2003.
5. Vu TH, Li T, Nguyen D, Nguyen BT, Yao XM, Hu JF and Hoffman AR: Symmetric and asymmetric DNA methylation in the human IGF2-H19 imprinted region. Genomics 64: 132-143, 2000.
6. Bell A and Felsenfeld G: Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405: 482-485, 2000.
7. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM and Tilghman SM: CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405: 486-489, 2000.
8. Szabo P, Tang SH, Rentsendorj A, Pfeifer GP and Mann JR: Maternal specific footprints at putative CTCF sites in the H19 imprinting control region give evidence for insulator function. Curr Biol 10: 607-610, 2000.
9. Cui H, Niemitz EL, Ravenel JD, Onyango P, Brandenburg SA, Lobanenkov VV and Feinberg AP: Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res 61: 4947-4950, 2001.
10. Ulaner GA, Yang Y, Hu JF, Li T, Vu TH and Hoffman AR: CTCF binding at the insulin-like growth factor-II (IGF2)/H19 imprinting control region is insufficient to regulate IGF2/H19 expression in human tissues. Endocrinology 144: 4420-4426, 2003.
11. Nakagawa H, Nuovo GJ, Zervos EE, Martin EW Jr, Salovaara R, Aaltonen LA and de la Chapelle A: Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 61: 6991-6995, 2001.
12. Feinberg AP: Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 98: 392-394, 2001.
13. Takai D, Gonzales FA, Tsai YC, Thayer MJ and Jones PA: Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 10: 2619-2626, 2001.
14. Fu VX, Dobosy JR, Desotelle JA, Almassi N, et al: Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res 68: 6797-6802, 2008.
15. Murrell A, Heeson S and Reik W, et al: Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops. Nat Genet 36: 889-893, 2004.
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics. CA Cancer J Clin 56: 106-130, 2006.
17. Bunting PS: Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 315: 71-97, 2002.
18. Manoharan M, Ramachandran K, Soloway MS and Singal R: Epigenetic targets in the diagnosis and treatment of prostate cancer. Int Braz J Urol 33: 11-18, 2007.
19. Wells J and Farnham PJ: Characterizing transcription factor binding sites using formaldehyde crosslinking and immuno-precipitation. Methods 26: 48-56, 2002.
20. Jarrard DF, Bussemakers MJ, Bova GS and Isaacs WB: Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res 1: 1471-1478, 1995.
21. Pant V, Kurukuti S, Pugacheva E, et al: Mutation of a single CTCF target site within the H19 imprinting control region leads to loss of Igf2 imprinting and complex patterns of de novo methylation upon maternal inheritance. Mol Cell Biol 24: 3497-3504, 2004.
22. Szabo PE, Tang SH, Silva FJ, Tsark WM and Mann JR: Role of CTCF binding sites in the Igf2/H19 imprinting control region. Mol Cell Biol 24: 4791-4800, 2004.
23. Esteves LI, Javaroni AC, Nishimoto IN, et al: DNA methylation in the CTCF-binding site I and the expression pattern of the H19 gene: does positive expression predict poor prognosis in early stage head and neck carcinomas? Mol Carcinog 44: 102-110, 2005.
24. Hancock AL, Brown KW, Moorwood K, et al: A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis. Hum Mol Genet 16: 343-354, 2007.
25. Cooper MJ, Fischer M, Komitowski D, et al: Developmentally imprinted genes as markers for bladder tumor progression. J Urol 155: 2120-2127, 1996.
26. Cho NY, Kim BH, Choi M, et al: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinico-pathological features. J Pathol 211: 269-277, 2007.
27. Ellinger J, Bastian PJ, Jurgan T, et al: CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71: 161-167, 2008.
28. Murell A: Genomic imprinting and cancer: from primordial germ cells to somatic cells. Scientific World J 6: 1888-1910, 2006.
29. Fahrner JA, Eguchi S, Herman JG and Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62: 7213-7218, 2002.
30. Nguyen TT, Cho K, Stratton SA and Barton MC: Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene. Mol Cell Biol 25: 2147-2157, 2005.
31. Dobosy JR, Fu VX, Desotelle JA, et al: A methyl-deficient diet modifies histone methylation and alters Igf2 and H19 repression in the prostate. Prostate 68: 1187-1195, 2008.
32. Guan M, Zhou X, Soulitzis N, Spandidos DA and Popescu NC: Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res 12: 1412-1419, 2006.
33. Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM and Singal R: Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer 5: 28, 2006.
34. Reibenwein J, Pils D and Horak P: Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67: 427-432, 2007.
35. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M and Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266, 2005.
36. Ferdinandusse S, Denis S, Ijlst L, Dacremont G, Waterham HR and Wanders RJ: Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 41: 1890-1896, 2000.
37. Xu J, Kalos M, Stolk JA, et al: Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 61: 1563-1568, 2001.
38. Luo J, Duggan DJ, Chen Y, et al: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61: 4683-4688, 2001.
39. Bull JH, Ellison G, Patel A, et al: Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 84: 1512-1519, 2001.
40. Luo JH: Gene expression alterations in human prostate cancer. Drugs Today (Barc) 38: 713-719, 2002.